This consent order formalizes a revised procedural timetable for the exchange of witness evidence in the complex multi-party litigation involving Bank of Baroda and the Neopharma/NMC Healthcare group entities.
What specific procedural dispute necessitated the consent order in Bank of Baroda v Neopharma (CFI 043/2020)?
The litigation involves a high-stakes dispute between the Bank of Baroda (DIFC Branch) and multiple defendants, including Neopharma LLC, NMC Healthcare LLC, New Medical Centre LLC, and Bavaguthu Raghuram Shetty. The matter, registered as CFI 043/2020, reached a juncture where the parties required an adjustment to the evidentiary timeline previously established by the Court. The dispute centers on the preparation and exchange of witness statements of fact and hearsay notices, which are critical components of the trial preparation process under the Rules of the DIFC Courts (RDC).
Following applications filed by the First Defendant (Neopharma LLC) and the Fourth Defendant (Bavaguthu Raghuram Shetty) on 27 March 2023, the parties reached a consensus to extend the deadlines for these filings. The Court formalized this agreement to ensure that all parties have sufficient time to finalize their witness evidence, thereby avoiding potential procedural prejudice. The order specifically addresses the timeline for primary witness statements and subsequent reply statements:
The time frame for signed statements of witnesses of fact and hearsay notices in accordance with RDC Part 29 of the Rules of the DIFC Courts in the matter of CFl-043-2020, shall be extended by four weeks i.e.,
4pm on 5 May 2023.
Which judicial authority presided over the issuance of the consent order in CFI 043/2020?
The consent order was issued by Assistant Registrar Delvin Sumo on 30 March 2023. While the underlying Case Management Order was originally issued by H.E. Justice Nassir Al Nasser on 17 October 2022, the specific procedural adjustment regarding witness evidence deadlines was processed through the Court of First Instance’s administrative registry mechanism, reflecting the parties' mutual agreement to the revised schedule.
What were the specific legal arguments advanced by Neopharma LLC and Bavaguthu Raghuram Shetty to justify the extension of time?
While the order is a consent-based instrument, the underlying applications (CFI-043-2020/11 and CFI-043-2020/12) filed by the Fourth and First Defendants, respectively, indicate a strategic necessity for additional time to comply with RDC Part 29. In complex commercial litigation of this nature, defendants often argue that the volume of documentation and the complexity of the factual matrix—particularly involving multiple corporate entities and individual defendants—require more than the standard period for the collation and verification of witness testimony.
By seeking an extension via consent, the parties effectively signaled to the Court that the additional four-week window is essential for the proper administration of justice and the integrity of the evidence to be presented at trial. This avoids the need for a contested hearing, allowing the parties to focus resources on the substantive preparation of their respective cases rather than procedural litigation.
What was the precise doctrinal issue regarding RDC Part 29 that the Court addressed in this order?
The Court was tasked with determining whether a four-week extension to the existing Case Management Order was compatible with the overriding objective of the RDC. The doctrinal issue is not one of substantive law, but rather the management of the Court’s calendar and the strict adherence to procedural deadlines. Under RDC Part 29, the Court maintains discretion to manage the exchange of witness statements to ensure fairness and efficiency. The legal question was whether the parties' agreed-upon extension would unduly delay the trial or prejudice the Claimant, Bank of Baroda, and whether the Court should exercise its discretion to permit the adjustment of the timetable to ensure that the evidence before the Court is complete and robust.
How did the Court apply its discretion to modify the existing Case Management Order?
The Court exercised its inherent case management powers to grant the extension, acknowledging the agreement between the Claimant and the Defendants. By formalizing the request, the Court ensured that the new deadlines are binding and enforceable, thereby maintaining the structure of the litigation while accommodating the practical realities of the parties' preparation. The reasoning follows the standard practice of the DIFC Courts to facilitate consensual procedural adjustments that do not compromise the trial date. The specific directive for the reply statements is as follows:
The time frame for any witness statement in reply shall be filed and served in accordance with RDC Part 29 of the Rules of the DIFC Courts in the matter of CFl-043-2020, shall be extended by four weeks i.e.,
4pm on 5 June 2023.
Which specific RDC rules and procedural frameworks were invoked in the Bank of Baroda v Neopharma order?
The order explicitly references RDC Part 29, which governs the rules regarding witness statements in the DIFC Courts. This part of the rules dictates the requirements for the content, format, and service of witness statements, including the necessity of hearsay notices where applicable. By citing RDC Part 29, the Court ensures that the extension remains strictly within the procedural framework of the DIFC, maintaining the consistency of the evidentiary record.
How does the application of RDC Part 29 in this case reflect the DIFC Courts' approach to witness evidence?
RDC Part 29 is designed to ensure that all parties have adequate notice of the evidence to be relied upon at trial. In this case, the Court’s application of the rule serves to balance the need for procedural speed with the necessity of allowing parties sufficient time to prepare comprehensive witness statements. By granting the extension, the Court implicitly recognized that the complexity of the Bank of Baroda’s claim against the Neopharma group necessitates a more flexible approach to the RDC Part 29 timeline than might be required in simpler, single-issue disputes.
What was the final disposition of the application and the impact on the litigation costs?
The Court granted the extension as requested by the parties, setting the new deadline for witness statements of fact and hearsay notices at 4:00 pm on 5 May 2023, and the deadline for witness statements in reply at 4:00 pm on 5 June 2023. Crucially, the Court ordered that there be "no order as to costs" regarding these applications. This reflects the consensual nature of the request, as neither party was forced to incur the costs of a contested procedural hearing. The parties also retained the "liberty to apply," allowing them to return to the Court should further procedural issues arise.
What are the wider implications for practitioners managing complex multi-party litigation in the DIFC?
This order serves as a reminder that the DIFC Courts prioritize the efficient, consensual resolution of procedural disputes. For practitioners, it demonstrates that when faced with complex evidence-gathering challenges, the most effective route is often to negotiate a revised timetable with opposing counsel and present it to the Court as a consent order. This approach minimizes judicial intervention, preserves costs, and maintains a cooperative atmosphere between the parties. Litigants should anticipate that the Court will generally support such requests provided they are well-reasoned and do not jeopardize the overall trial schedule.
Where can I read the full judgment in Bank of Baroda v Neopharma [2023] DIFC CFI 043?
The full text of the consent order can be accessed via the DIFC Courts website: https://www.difccourts.ae/rules-decisions/judgments-orders/court-first-instance/cfi-0432020-bank-baroda-difc-branch-v-1-neopharma-llc-2-nmc-healthcare-llc-3-new-medical-centre-llc-4-bavaguthu-raghuram-shetty-4
CDN link: https://littdb.sfo2.cdn.digitaloceanspaces.com/litt/AE/DIFC/judgments/court-first-instance/DIFC_CFI-043-2020_20230330.txt
Cases referred to in this judgment:
| Case | Citation | How used |
|---|---|---|
| None cited | N/A | N/A |
Legislation referenced:
- Rules of the DIFC Courts (RDC) Part 29